TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, Şenbabaoğlu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, Höglund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS, Bourgon R, Powles T.
Nature
554 :
2018
544-548
1996
LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8<sup>+</sup> T cell tumor-infiltration impairing anti-PD1 therapy.
Pascual-García M, Bonfill-Teixidor E, Planas-Rigol E, Rubio-Perez C, Iurlaro R, Arias A, Cuartas I, Sala-Hojman A, Escudero L, Martínez-Ricarte F, Huber-Ruano I, Nuciforo P, Pedrosa L, Marques C, Braña I, Garralda E, Vieito M, Squatrito M, Pineda E, Graus F, Espejo C, Sahuquillo J, Tabernero J, Seoane J.
Nat Commun
10 :
2019
2416
71
Escape from nonsense-mediated decay associates with anti-tumor immunogenicity.
Litchfield K, Reading JL, Lim EL, Xu H, Liu P, Al-Bakir M, Wong YNS, Rowan A, Funt SA, Merghoub T, Perkins D, Lauss M, Svane IM, Jönsson G, Herrero J, Larkin J, Quezada SA, Hellmann MD, Turajlic S, Swanton C.
Nat Commun
11 :
2020
3800
40
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer.
Ahn SG, Kim SK, Shepherd JH, Cha YJ, Bae SJ, Kim C, Jeong J, Perou CM.
Breast Cancer Res Treat
188 :
2021
165-178
9
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade.
Banchereau R, Chitre AS, Scherl A, Wu TD, Patil NS, de Almeida P, Kadel Iii EE, Madireddi S, Au-Yeung A, Takahashi C, Chen YJ, Modrusan Z, McBride J, Nersesian R, El-Gabry EA, Robida MD, Hung JC, Kowanetz M, Zou W, McCleland M, Caplazi P, Eshgi ST, Koeppen H, Hegde PS, Mellman I, Mathews WR, Powles T, Mariathasan S, Grogan J, O'Gorman WE.
J Immunother Cancer
9 :
2021
e002231
35
Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers.
McGrail DJ, Pilié PG, Dai H, Lam TNA, Liang Y, Voorwerk L, Kok M, Zhang XH, Rosen JM, Heimberger AB, Peterson CB, Jonasch E, Lin SY.
Sci Transl Med
13 :
2021
eabe6201
9
<i>ACSL4</i> Expression Is Associated With CD8+ T Cell Infiltration and Immune Response in Bladder Cancer.
Luo W, Wang J, Dai X, Zhang H, Qu Y, Xiao W, Ye D, Zhu Y.
Front Oncol
11 :
2021
754845
3
Accounting for B-cell Behavior and Sampling Bias Predicts Anti-PD-L1 Response in Bladder Cancer.
Dyugay IA, Lukyanov DK, Turchaninova MA, Serebrovskaya EO, Bryushkova EA, Zaretsky AR, Khalmurzaev O, Matveev VB, Shugay M, Shelyakin PV, Chudakov DM.
Cancer Immunol Res
10 :
2022
343-353
5
Follicular Helper T-Cell-Based Classification of Endometrial Cancer Promotes Precise Checkpoint Immunotherapy and Provides Prognostic Stratification.
Chen Y, You S, Li J, Zhang Y, Kokaraki G, Epstein E, Carlson J, Huang WK, Haglund F.
Front Immunol
12 :
2021
788959
5
Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors.
Nikolos F, Hayashi K, Hoi XP, Alonzo ME, Mo Q, Kasabyan A, Furuya H, Trepel J, Di Vizio D, Guarnerio J, Theodorescu D, Rosser C, Apolo A, Galsky M, Chan KS.
Nat Commun
13 :
2022
1487
9
Targeting TCTP sensitizes tumor to T cell-mediated therapy by reversing immune-refractory phenotypes.
Lee HJ, Song KH, Oh SJ, Kim S, Cho E, Kim J, Park YG, Lee KM, Yee C, Song SH, Chang S, Choi J, Jung ST, Kim TW.
Nat Commun
13 :
2022
2127
2
Pyroptosis-Related Signature Predicts Prognosis and Immunotherapy Efficacy in Muscle-Invasive Bladder Cancer.
Zhang Q, Tan Y, Zhang J, Shi Y, Qi J, Zou D, Ci W.
Front Immunol
13 :
2022
782982
9
Prediction of the Immune Phenotypes of Bladder Cancer Patients for Precision Oncology.
Cho H, Tong F, You S, Jung S, Kim WH, Kim J.
IEEE Open J Eng Med Biol
3 :
2022
47-57
0
Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review.
Kovács SA, Győrffy B.
J Transl Med
20 :
2022
249
11
Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients.
Seitz RS, Hurwitz ME, Nielsen TJ, Bailey DB, Varga MG, Ring BZ, Metts CF, Schweitzer BL, McGregor K, Ross DT.
J Transl Med
20 :
2022
370
2
Lactate: A regulator of immune microenvironment and a clinical prognosis indicator in colorectal cancer.
Zhu D, Jiang Y, Cao H, Yang J, Shu Y, Feng H, Yang X, Sun X, Shao M.
Front Immunol
13 :
2022
876195
3
Conserved angio-immune subtypes of the tumor microenvironment predict response to immune checkpoint blockade therapy.
Subramanian M, Kabir AU, Barisas D, Krchma K, Choi K.
Cell Rep Med
4 :
2023
100896
3
M7G-related molecular subtypes can predict the prognosis and correlate with immunotherapy and chemotherapy responses in bladder cancer patients.
Li DX, Feng DC, Wang XM, Wu RC, Zhu WZ, Chen K, Han P.
Eur J Med Res
28 :
2023
55
1
The ratio of adaptive to innate immune cells differs between genders and associates with improved prognosis and response to immunotherapy.
Ahrenfeldt J, Christensen DS, Østergaard AB, Kisistók J, Sokač M, Birkbak NJ.
PLoS One
18 :
2023
e0281375
0
Overcoming resistance to immunotherapy by targeting GPR84 in myeloid-derived suppressor cells.
Qin G, Liu S, Liu J, Hu H, Yang L, Zhao Q, Li C, Zhang B, Zhang Y.
Signal Transduct Target Ther
8 :
2023
164
0
In situ tumour arrays reveal early environmental control of cancer immunity.
Ortiz-Muñoz G, Brown M, Carbone CB, Pechuan-Jorge X, Rouilly V, Lindberg H, Ritter AT, Raghupathi G, Sun Q, Nicotra T, Mantri SR, Yang A, Doerr J, Nagarkar D, Darmanis S, Haley B, Mariathasan S, Wang Y, Gomez-Roca C, de Andrea CE, Spigel D, Wu T, Delamarre L, Schöneberg J, Modrusan Z, Price R, Turley SJ, Mellman I, Moussion C.
Nature
618 :
2023
827-833
0
Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy.
Schina A, Sztupinszki Z, Marie Svane I, Szallasi Z, Jönsson G, Donia M.
J Immunother Cancer
11 :
2023
e006941
0